These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 33740548)

  • 1. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
    Liu J; Chen C; Wang D; Zhang J; Zhang T
    Eur J Med Chem; 2021 May; 217():113329. PubMed ID: 33740548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib.
    Dostálová H; Kryštof V
    Hematol Oncol; 2024 Jul; 42(4):e3294. PubMed ID: 38847437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of Bruton's tyrosine kinase in the immune system and disease.
    McDonald C; Xanthopoulos C; Kostareli E
    Immunology; 2021 Dec; 164(4):722-736. PubMed ID: 34534359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases.
    De Bondt M; Renders J; Struyf S; Hellings N
    Autoimmun Rev; 2024 May; 23(5):103532. PubMed ID: 38521213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer.
    Ghoshdastidar K; Patel H; Bhayani H; Patel A; Thakkar K; Patel D; Sharma M; Singh J; Mohapatra J; Chatterjee A; Patel D; Bahekar R; Sharma R; Gupta L; Patel N; Giri P; Srinivas NR; Jain M; Bandyopadhyay D; Patel PR; Desai RC
    Pharmacol Res Perspect; 2020 Aug; 8(4):e00565. PubMed ID: 32790160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Pteridine-7(8
    Dou D; Diao Y; Sha W; Su R; Tong L; Li W; Leng L; Xie L; Yu Z; Song H; Shen Z; Zhu L; Zhao Z; Xie H; Chen Z; Li H; Xu Y
    J Med Chem; 2022 Feb; 65(3):2694-2709. PubMed ID: 35099969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Biological Evaluation of Oxindole Sulfonamide Derivatives as Bruton's Tyrosine Kinase Inhibitors.
    Koraboina CP; Maddipati VC; Annadurai N; Gurská S; Džubák P; Hajdúch M; Das V; Gundla R
    ChemMedChem; 2024 Jan; 19(1):e202300511. PubMed ID: 37916435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK.
    Forster M; Liang XJ; Schröder M; Gerstenecker S; Chaikuad A; Knapp S; Laufer S; Gehringer M
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances.
    Schaff L; Nayak L; Grommes C
    Leuk Lymphoma; 2024 Jul; 65(7):882-894. PubMed ID: 38597202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
    Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D
    Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revealing the Role of the Arg and Lys in Shifting Paradigm from BTK Selective Inhibition to the BTK/HCK Dual Inhibition - Delving into the Inhibitory Activity of KIN-8194 against BTK, and HCK in the Treatment of Mutated
    Elamin G; Aljoundi A; Alahmdi MI; Abo-Dya NE; Soliman MES
    Anticancer Agents Med Chem; 2024; 24(11):813-825. PubMed ID: 36752293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Novel Bruton's Tyrosine Kinase PROTACs with Enhanced Selectivity and Cellular Efficacy.
    Li YQ; Lannigan WG; Davoodi S; Daryaee F; Corrionero A; Alfonso P; Rodriguez-Santamaria JA; Wang N; Haley JD; Tonge PJ
    J Med Chem; 2023 Jun; 66(11):7454-7474. PubMed ID: 37195170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's Tyrosine Kinase Inhibitors in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Meta-analysis and Systematic Review.
    Guo HP; Dang XL; Kang L; Liu C; Liu XW
    World Neurosurg; 2024 Aug; 188():161-169. PubMed ID: 38641241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent research of BTK inhibitors: Methods of structural design, pharmacological activities, manmade derivatives and structure-activity relationship.
    Wang L; Zhang Z; Yu D; Yang L; Li L; He Y; Shi J
    Bioorg Chem; 2023 Sep; 138():106577. PubMed ID: 37178649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel dual Bruton's tyrosine kinase (BTK) and Janus kinase 3 (JAK3) inhibitors as a promising strategy for rheumatoid arthritis.
    Liang T; Cen L; Wang J; Cheng M; Guo W; Wang W; Yu C; Zhang H; Wang Y; Hao Z; Jin J; Wu Y; Jiang T; Zhu Q; Xu Y
    Bioorg Med Chem; 2023 Dec; 96():117354. PubMed ID: 37944414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies.
    Alu A; Lei H; Han X; Wei Y; Wei X
    J Hematol Oncol; 2022 Oct; 15(1):138. PubMed ID: 36183125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Structure-Activity Investigation of the Fungal Metabolite (-)-TAN-2483B: Inhibition of Bruton's Tyrosine Kinase.
    McCone JAJ; Teesdale-Spittle PH; Flanagan JU; Harvey JE
    Chemistry; 2024 Jun; 30(35):e202401051. PubMed ID: 38629656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib.
    Lin DY; Andreotti AH
    PLoS One; 2023; 18(8):e0290872. PubMed ID: 37651403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease.
    Neys SFH; Rip J; Hendriks RW; Corneth OBJ
    Drugs; 2021 Sep; 81(14):1605-1626. PubMed ID: 34609725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility to Cryptococcus neoformans Infection with Bruton's Tyrosine Kinase Inhibition.
    Messina JA; Giamberardino CD; Tenor JL; Toffaletti DL; Schell WA; Asfaw YG; Palmucci JR; Lionakis MS; Perfect JR
    Infect Immun; 2023 Aug; 91(8):e0004223. PubMed ID: 37404186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.